Friday, 23 Mar 2018

You are here

29 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from This week's report discusses regulatory actions by NICE and FDA, higher death rates in RA and psoriasis, increased risk of RA with Asthma, rising numbers for OA, RA, and STDs.

  1. In RA, Smoking status recorded in 40%; cessation counseling in only 10% & was less likely when RA was controlled. 
  2. ~1/3 RA pts rank their Disease activity higher than their Rheumatologist; more likely seronegative RA, those in LDAS with FM, Depression, high pain scores. 
  3. Higher MASEI (enthesitis) scores in PsA associated with more Joint damage, ankylosis, arthritis mutilans periostitis, axial Disease. 
  4. Review shows antiphopholipid Abs associated with and increased risk of idiopathic pulm arterial HTN, left-side valvular heart dz
  5. CDC: STDs new record high #s in 2016 - chlamydia (1.6mil), gonorrhea (470k) & syphilis (28k); more screening urged
  6. In Australia from 2015 to 2030, OA numbers are expected to increase 41%; RA by 37%, with cost of care rising by 37% for both.
  7. Mayo: 1996 to 2013, 58 cases of AAV in Olmstead Co - 23 GPA, 28 MPA & 7 EGPA. 60% MPO+, 30% PR3+: Prev 42.1/100,000
  8. Olmstead Co. Mayo Clinic study shows asthma significantly associated with increased risk of RA (adj OR 1.74) 
  9. Kevzara (sarilumab) has been recommended by UK NICE for use with MTX in adults with severe, active RA
  10. FDA Panel Backs New Zoster Subunit Vaccine
  11. Sirukumab Turned Down by FDA
  12.  Psoriasis Increases Risk of Major Adverse Cardiovascular Events  
  13. Increased Deaths in RA, Despite Decreasing Mortality Rates
  14. No Cancer Risk With Biologic Use
  15. The DownEaster Meeting – Westborough, MA  14 October 2017  
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review - 23 March 2018

Dr. Jack Cush reviews the highlights from the news, journals and major meetings. New announcements and approval from the FDA; novel associations between ANCA vasculitis and thyroid disease; flare rates after arthroplasty; and pregnancy outcomes for men and women.

MMWR: Arthritis Prevalence Increases and Varies Widely

MMWR reports that In 2015, the number of adults with arthritis continued to increase; with marked geographic variability in arthritis estimates with gaps in arthritis management.

The CDC estimates that physician-diagnosed arthritis affects 54 million of adults in the United States with an annual cost of approximately $300 billion annually.

The RheumNow Week in Review - 16 March 2018

Dr. Jack Cush reviews the highlights from the news, journals and major meetings. Bigtime rheumatologic lessons with tales from intestinal crypts, the friendly skies & the hips of hockey players. Also the microbiome and lupus, benefits of ENT findings with GPA and rare risk of opportunistic infections with biologics.

The RheumNow Week in Review - 9 March 2018

Dr. Jack Cush reviews highlights, news and recent research published this past week on This week's report includes news on new regulatory changes, new indication for tofacitinib, the rise and deficits of opioids and the benefits of fish and bariatric surgery.

ACR Responds to Association Health Plans Proposed Rule

In comments submitted today to the US Department of Labor in response to its Association Health Plans (AHP) proposed rule, the American College of Rheumatology urged Administration officials to protect essential health benefits and other consumer protections that make it possible for individuals living with rheumatic diseases to access comprehensive and affordable healthcare.